134 related articles for article (PubMed ID: 32749710)
1. Decompensated cirrhosis and liver transplantation negatively impact in DAA treatment response: Real-world experience from HCV-LALREAN cohort.
Ridruejo E; Piñero F; Mendizabal M; Cheinquer H; Wolff FH; Anders M; Reggiardo V; Ameigeiras B; Palazzo A; Alonso C; Schinoni MI; Zuain MGV; Tanno F; Figueroa S; Santos L; Peralta M; Soza A; Vistarini C; Adrover R; Fernández N; Perez D; Hernández N; Estepo C; Bruno A; Descalzi V; Sixto M; Borzi S; Cocozzella D; Zerega A; de Araujo A; Varón A; Silva M;
J Med Virol; 2020 Dec; 92(12):3545-3555. PubMed ID: 32749710
[TBL] [Abstract][Full Text] [Related]
2. Direct-Acting Antiviral Therapy for Patients with Chronic Hepatitis C Infection and Decompensated Cirrhosis.
Pearlman BL
Dig Dis Sci; 2024 May; 69(5):1551-1561. PubMed ID: 38580885
[TBL] [Abstract][Full Text] [Related]
3. Assessment of factors affecting response of direct-acting antivirals in chronic hepatitis C patients.
Jain N; Garg R; Singh GP; Kaur S; Chawla SPS; Padda P
Ann Afr Med; 2023; 22(4):456-464. PubMed ID: 38358146
[TBL] [Abstract][Full Text] [Related]
4. Impact of sustained virologic response on glucose parameters among patients with chronic hepatitis C treated with direct-acting antivirals.
Benetti F; de Araújo A; de Maman Júnior I; Coelho Borges Cheinquer C; Herz Wolff F; Cheinquer H
Arch Endocrinol Metab; 2024 May; 68():e220480. PubMed ID: 38709148
[TBL] [Abstract][Full Text] [Related]
5. Sustained Virologic Response and Costs Associated with Direct-Acting Antivirals for Chronic Hepatitis C Infection in Oklahoma Medicaid.
Pham TT; Keast SL; Farmer KC; Thompson DM; Rathbun RC; Nesser NJ; Holderread BP; Skrepnek GH
J Manag Care Spec Pharm; 2018 Jul; 24(7):664-676. PubMed ID: 29952711
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
Krassenburg LAP; Maan R; Ramji A; Manns MP; Cornberg M; Wedemeyer H; de Knegt RJ; Hansen BE; Janssen HLA; de Man RA; Feld JJ; van der Meer AJ
J Hepatol; 2021 May; 74(5):1053-1063. PubMed ID: 33242501
[TBL] [Abstract][Full Text] [Related]
7. Results of Sofosbuvir Plus Ribavirin in Patients With Hepatitis C Related Decompensated Cirrhosis.
Tmu N; Kumar A; Sharma P; Singla V; Bansal N; Arora A
J Clin Exp Hepatol; 2019; 9(1):4-12. PubMed ID: 30765933
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure.
Lu M; Wu KH; Li J; Moorman AC; Spradling PR; Teshale EH; Boscarino JA; Daida YG; Schmidt MA; Rupp LB; Zhang T; Trudeau S; Gordon SC
J Viral Hepat; 2019 Oct; 26(10):1210-1217. PubMed ID: 31197910
[TBL] [Abstract][Full Text] [Related]
9. Potential Liver Transplant Recipients with Hepatitis C: Should They Be Treated Before or After Transplantation?
Anand AC
J Clin Exp Hepatol; 2017 Mar; 7(1):42-54. PubMed ID: 28348470
[TBL] [Abstract][Full Text] [Related]
10. Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan.
Chen CY; Huang CF; Cheng PN; Tseng KC; Lo CC; Kuo HT; Huang YH; Tai CM; Peng CY; Bair MJ; Chen CH; Yeh ML; Lin CL; Lin CY; Lee PL; Chong LW; Hung CH; Huang JF; Yang CC; Hu JT; Lin CW; Chen CT; Wang CC; Su WW; Hsieh TY; Lin CL; Tsai WL; Lee TH; Chen GY; Wang SJ; Chang CC; Mo LR; Yang SS; Wu WC; Huang CS; Hsiung CK; Kao CN; Tsai PC; Liu CH; Lee MH; Liu CJ; Dai CY; Kao JH; Chuang WL; Lin HC; Yu ML
Liver Int; 2021 Jun; 41(6):1265-1277. PubMed ID: 33655714
[TBL] [Abstract][Full Text] [Related]
11. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure.
Degasperi E; Spinetti A; Lombardi A; Landonio S; Rossi MC; Pasulo L; Pozzoni P; Giorgini A; Fabris P; Romano A; Lomonaco L; Puoti M; Vinci M; Gatti F; Carolo G; Zoncada A; Bonfanti P; Russo FP; Aghemo A; Soria A; Centenaro R; Maggiolo F; Rovere P; Pasin F; Paon V; Faggiano G; Vario A; Grossi G; Soffredini R; Carriero C; Paolucci S; Noventa F; Alberti A; Lampertico P; Fagiuoli S;
J Hepatol; 2019 Dec; 71(6):1106-1115. PubMed ID: 31433303
[TBL] [Abstract][Full Text] [Related]
12. DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.
Verna EC; Morelli G; Terrault NA; Lok AS; Lim JK; Di Bisceglie AM; Zeuzem S; Landis CS; Kwo P; Hassan M; Manns MP; Vainorius M; Akushevich L; Nelson DR; Fried MW; Reddy KR
J Hepatol; 2020 Sep; 73(3):540-548. PubMed ID: 32243960
[TBL] [Abstract][Full Text] [Related]
13. Impact of Direct Acting Antiviral Therapy for Treatment of Hepatitis C Genotypes 1, 3 and 4: A Real Life Experience from India.
Mehta V; Mahajan R; Midha V; Narang V; Kaur K; Singh A; Malhotra A; Parvez A; Sood A
J Clin Exp Hepatol; 2018 Mar; 8(1):7-14. PubMed ID: 29743791
[TBL] [Abstract][Full Text] [Related]
14. Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network.
Kondili LA; Gaeta GB; Brunetto MR; Di Leo A; Iannone A; Santantonio TA; Giammario A; Raimondo G; Filomia R; Coppola C; Amoruso DC; Blanc P; Del Pin B; Chemello L; Cavalletto L; Morisco F; Donnarumma L; Rumi MG; Gasbarrini A; Siciliano M; Massari M; Corsini R; Coco B; Madonia S; Cannizzaro M; Zignego AL; Monti M; Russo FP; Zanetto A; Persico M; Masarone M; Villa E; Bernabucci V; Taliani G; Biliotti E; Chessa L; Pasetto MC; Andreone P; Margotti M; Brancaccio G; Ieluzzi D; Borgia G; Zappulo E; Calvaruso V; Petta S; Falzano L; Quaranta MG; Weimer LE; Rosato S; Vella S; Giannini EG
PLoS One; 2017; 12(10):e0185728. PubMed ID: 28977040
[TBL] [Abstract][Full Text] [Related]
15. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.
Maan R; van Tilborg M; Deterding K; Ramji A; van der Meer AJ; Wong F; Fung S; Sherman M; Manns MP; Cornberg M; Hansen BE; Wedemeyer H; Janssen HL; de Knegt RJ; Feld JJ
Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1821-1830.e6. PubMed ID: 27404965
[TBL] [Abstract][Full Text] [Related]
16. Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort.
Quaranta MG; Ferrigno L; Tata X; D'Angelo F; Coppola C; Ciancio A; Bruno SR; Loi M; Giorgini A; Margotti M; Cossiga V; Brancaccio G; Dallio M; De Siena M; Cannizzaro M; Cavalletto L; Massari M; Mazzitelli M; De Leo P; Laccabue D; Baiocchi L; Kondili LA
BMC Infect Dis; 2021 May; 21(1):413. PubMed ID: 33947337
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
Llaneras J; Riveiro-Barciela M; Lens S; Diago M; Cachero A; García-Samaniego J; Conde I; Arencibia A; Arenas J; Gea F; Torras X; Luis Calleja J; Antonio Carrión J; Fernández I; María Morillas R; Rosales JM; Carmona I; Fernández-Rodríguez C; Hernández-Guerra M; Llerena S; Bernal V; Turnes J; González-Santiago JM; Montoliu S; Figueruela B; Badia E; Delgado M; Fernández-Bermejo M; Iñarrairaegui M; Pascasio JM; Esteban R; Mariño Z; Buti M
J Hepatol; 2019 Oct; 71(4):666-672. PubMed ID: 31203153
[TBL] [Abstract][Full Text] [Related]
18. Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group.
Tada T; Kurosaki M; Nakamura S; Hasebe C; Kojima Y; Furuta K; Kobashi H; Kimura H; Ogawa C; Yagisawa H; Uchida Y; Joko K; Akahane T; Arai H; Marusawa H; Narita R; Ide Y; Sato T; Kusakabe A; Tsuji K; Mori N; Kondo M; Mitsuda A; Izumi N
J Med Virol; 2021 Nov; 93(11):6247-6256. PubMed ID: 34170517
[TBL] [Abstract][Full Text] [Related]
19. Genotypes of Hepatitis C Virus and Efficacy of Direct-Acting Antiviral Drugs among Chronic Hepatitis C Patients in a Tertiary Care Hospital.
Hawsawi NM; Saber T; Salama HM; Fouad WS; Hagag HM; Alhuthali HM; Eed EM; Saber T; Ismail KA; Al Qurashi HH; Altowairqi S; Samaha M; El-Hossary D
Trop Med Infect Dis; 2023 Jan; 8(2):. PubMed ID: 36828508
[TBL] [Abstract][Full Text] [Related]
20. Direct-acting antiviral therapy for hepatitis C: The initial experience of the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa.
Sonderup MW; Gogela N; Nordien R; Smuts H; Korsman S; Hardie D; Spearman CW
S Afr Med J; 2020 Jan; 110(2):112-117. PubMed ID: 32657680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
